ID   PHAG1_RAT               Reviewed;         424 AA.
AC   Q9JM80;
DT   20-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   24-JUL-2024, entry version 104.
DE   RecName: Full=Phosphoprotein associated with glycosphingolipid-enriched microdomains 1;
DE   AltName: Full=Csk-binding protein;
DE   AltName: Full=Transmembrane phosphoprotein Cbp;
GN   Name=Pag1; Synonyms=Cbp, Pag;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], IDENTIFICATION BY MASS SPECTROMETRY,
RP   INTERACTION WITH CSK, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, MUTAGENESIS
RP   OF TYR-107; TYR-165; TYR-183; TYR-224; TYR-296; TYR-314; TYR-351; TYR-381
RP   AND TYR-409, PHOSPHORYLATION AT TYR-314, AND FUNCTION.
RC   TISSUE=Brain;
RX   PubMed=10801129; DOI=10.1038/35010121;
RA   Kawabuchi M., Satomi Y., Takao T., Shimonishi Y., Nada S., Nagai K.,
RA   Tarakhovsky A., Okada M.;
RT   "Transmembrane phosphoprotein Cbp regulates the activities of Src-family
RT   tyrosine kinases.";
RL   Nature 404:999-1003(2000).
RN   [2]
RP   PHOSPHORYLATION AT TYR-165; TYR-183; TYR-224; TYR-314; TYR-381 AND TYR-409,
RP   AND FUNCTION.
RX   PubMed=10918051; DOI=10.1074/jbc.c000326200;
RA   Takeuchi S., Takayama Y., Ogawa A., Tamura K., Okada M.;
RT   "Transmembrane phosphoprotein Cbp positively regulates the activity of the
RT   carboxyl-terminal Src kinase, Csk.";
RL   J. Biol. Chem. 275:29183-29186(2000).
RN   [3]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, INTERACTION WITH CSK,
RP   PHOSPHORYLATION, AND FUNCTION.
RX   PubMed=11859092; DOI=10.4049/jimmunol.168.5.2087;
RA   Ohtake H., Ichikawa N., Okada M., Yamashita T.;
RT   "Transmembrane phosphoprotein Csk-binding protein/phosphoprotein associated
RT   with glycosphingolipid-enriched microdomains as a negative feedback
RT   regulator of mast cell signaling through the FcepsilonRI.";
RL   J. Immunol. 168:2087-2090(2002).
RN   [4]
RP   INTERACTION WITH CSK, PHOSPHORYLATION, AND MUTAGENESIS OF TYR-314.
RX   PubMed=14613929; DOI=10.1074/jbc.m311278200;
RA   Matsuoka H., Nada S., Okada M.;
RT   "Mechanism of Csk-mediated down-regulation of Src family tyrosine kinases
RT   in epidermal growth factor signaling.";
RL   J. Biol. Chem. 279:5975-5983(2004).
RN   [5]
RP   INTERACTION WITH LYN AND CSK, AND PHOSPHORYLATION AT TYR-107 AND TYR-314.
RX   PubMed=16920712; DOI=10.1074/jbc.m602637200;
RA   Ingley E., Schneider J.R., Payne C.J., McCarthy D.J., Harder K.W.,
RA   Hibbs M.L., Klinken S.P.;
RT   "Csk-binding protein mediates sequential enzymatic down-regulation and
RT   degradation of Lyn in erythropoietin-stimulated cells.";
RL   J. Biol. Chem. 281:31920-31929(2006).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-52; SER-63 AND SER-157, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Negatively regulates TCR (T-cell antigen receptor)-mediated
CC       signaling in T-cells and FCER1 (high affinity immunoglobulin epsilon
CC       receptor)-mediated signaling in mast cells. Promotes CSK activation and
CC       recruitment to lipid rafts, which results in LCK inhibition. Inhibits
CC       immunological synapse formation by preventing dynamic arrangement of
CC       lipid raft proteins. May be involved in cell adhesion signaling.
CC       {ECO:0000269|PubMed:10801129, ECO:0000269|PubMed:10918051,
CC       ECO:0000269|PubMed:11859092}.
CC   -!- SUBUNIT: Interacts with NHERF1/EBP50. In resting T-cells, part of a
CC       PAG1-NHERF1-MSN complex which is disrupted upon TCR activation (By
CC       similarity). When phosphorylated, interacts with CSK. Identified in a
CC       complex with LYN and STAT3 (By similarity). Interacts with LYN.
CC       {ECO:0000250, ECO:0000269|PubMed:10801129, ECO:0000269|PubMed:11859092,
CC       ECO:0000269|PubMed:14613929, ECO:0000269|PubMed:16920712}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10801129,
CC       ECO:0000269|PubMed:11859092}; Single-pass type III membrane protein
CC       {ECO:0000269|PubMed:10801129, ECO:0000269|PubMed:11859092}.
CC       Note=Present in lipid rafts.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed, with highest levels in
CC       developing brain, lung, thymus, spleen and testis. Present in mast
CC       cells. {ECO:0000269|PubMed:10801129, ECO:0000269|PubMed:11859092}.
CC   -!- PTM: Palmitoylated. {ECO:0000250}.
CC   -!- PTM: Phosphorylated by FYN on Tyr-314 in resting T-cells; which
CC       promotes interaction with CSK. Dephosphorylated by PTPRC/CD45 upon TCR
CC       activation; which leads to CSK dissociation. May also be
CC       dephosphorylated by PTPN11. Hyperphosphorylated in mast cells upon
CC       FCER1 activation. Phosphorylated by LYN in response to EPO.
CC       {ECO:0000269|PubMed:10801129, ECO:0000269|PubMed:10918051,
CC       ECO:0000269|PubMed:11859092, ECO:0000269|PubMed:14613929,
CC       ECO:0000269|PubMed:16920712}.
CC   -!- CAUTION: In contrast to the human ortholog, does not seem to interact
CC       with FYN. {ECO:0000305|PubMed:10801129}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB038038; BAA95413.1; -; mRNA.
DR   RefSeq; NP_071589.1; NM_022253.1.
DR   PDB; 2RSY; NMR; -; B=288-321.
DR   PDBsum; 2RSY; -.
DR   AlphaFoldDB; Q9JM80; -.
DR   BMRB; Q9JM80; -.
DR   SMR; Q9JM80; -.
DR   BioGRID; 248938; 2.
DR   STRING; 10116.ENSRNOP00000071506; -.
DR   iPTMnet; Q9JM80; -.
DR   PhosphoSitePlus; Q9JM80; -.
DR   PaxDb; 10116-ENSRNOP00000065200; -.
DR   Ensembl; ENSRNOT00000119112.1; ENSRNOP00000079316.1; ENSRNOG00000061328.2.
DR   Ensembl; ENSRNOT00055002932; ENSRNOP00055002209; ENSRNOG00055001812.
DR   Ensembl; ENSRNOT00060002986; ENSRNOP00060001973; ENSRNOG00060001924.
DR   Ensembl; ENSRNOT00065021892; ENSRNOP00065016968; ENSRNOG00065013316.
DR   GeneID; 64019; -.
DR   KEGG; rno:64019; -.
DR   AGR; RGD:620394; -.
DR   CTD; 55824; -.
DR   RGD; 620394; Pag1.
DR   eggNOG; ENOG502QUCZ; Eukaryota.
DR   GeneTree; ENSGT00390000002061; -.
DR   InParanoid; Q9JM80; -.
DR   OMA; QCRDITR; -.
DR   OrthoDB; 5352799at2759; -.
DR   PhylomeDB; Q9JM80; -.
DR   Reactome; R-RNO-180292; GAB1 signalosome.
DR   Reactome; R-RNO-202427; Phosphorylation of CD3 and TCR zeta chains.
DR   EvolutionaryTrace; Q9JM80; -.
DR   PRO; PR:Q9JM80; -.
DR   Proteomes; UP000002494; Chromosome 2.
DR   GO; GO:0045121; C:membrane raft; ISO:RGD.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0042169; F:SH2 domain binding; ISO:RGD.
DR   GO; GO:0005068; F:transmembrane receptor protein tyrosine kinase adaptor activity; TAS:RGD.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0035556; P:intracellular signal transduction; ISO:RGD.
DR   GO; GO:0050868; P:negative regulation of T cell activation; ISO:RGD.
DR   GO; GO:0050863; P:regulation of T cell activation; ISO:RGD.
DR   InterPro; IPR032748; PAG.
DR   PANTHER; PTHR16322; PHOSPHOPROTEIN ASSOCIATED WITH GLYCOSPHINGOLIPID-ENRICHED MICRODOMAINS 1; 1.
DR   PANTHER; PTHR16322:SF0; PHOSPHOPROTEIN ASSOCIATED WITH GLYCOSPHINGOLIPID-ENRICHED MICRODOMAINS 1; 1.
DR   Pfam; PF15347; PAG; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Cell membrane; Immunity; Lipoprotein;
KW   Membrane; Palmitate; Phosphoprotein; Reference proteome; Signal-anchor;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..424
FT                   /note="Phosphoprotein associated with glycosphingolipid-
FT                   enriched microdomains 1"
FT                   /id="PRO_0000083340"
FT   TOPO_DOM        1..17
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        18..38
FT                   /note="Helical; Signal-anchor for type III membrane
FT                   protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        39..424
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          194..347
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          314..317
FT                   /note="Interaction with CSK"
FT   REGION          361..424
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          422..424
FT                   /note="Interaction with NHERF1"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        213..236
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        266..284
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        309..347
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        373..389
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         52
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         63
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         107
FT                   /note="Phosphotyrosine; by LYN"
FT                   /evidence="ECO:0000269|PubMed:16920712"
FT   MOD_RES         157
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         165
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:10918051"
FT   MOD_RES         183
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:10918051"
FT   MOD_RES         224
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:10918051"
FT   MOD_RES         226
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9NWQ8"
FT   MOD_RES         314
FT                   /note="Phosphotyrosine; by FYN and LYN"
FT                   /evidence="ECO:0000269|PubMed:10801129,
FT                   ECO:0000269|PubMed:10918051, ECO:0000269|PubMed:16920712"
FT   MOD_RES         346
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3U1F9"
FT   MOD_RES         351
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9NWQ8"
FT   MOD_RES         381
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:10918051"
FT   MOD_RES         409
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:10918051"
FT   LIPID           39
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   LIPID           42
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   MUTAGEN         107
FT                   /note="Y->F: No effect on interaction with CSK."
FT                   /evidence="ECO:0000269|PubMed:10801129"
FT   MUTAGEN         165
FT                   /note="Y->F: No effect on interaction with CSK."
FT                   /evidence="ECO:0000269|PubMed:10801129"
FT   MUTAGEN         183
FT                   /note="Y->F: No effect on interaction with CSK."
FT                   /evidence="ECO:0000269|PubMed:10801129"
FT   MUTAGEN         224
FT                   /note="Y->F: No effect on interaction with CSK."
FT                   /evidence="ECO:0000269|PubMed:10801129"
FT   MUTAGEN         296
FT                   /note="Y->F: No effect on interaction with CSK."
FT                   /evidence="ECO:0000269|PubMed:10801129"
FT   MUTAGEN         314
FT                   /note="Y->F: Abolishes interaction with CSK."
FT                   /evidence="ECO:0000269|PubMed:10801129,
FT                   ECO:0000269|PubMed:14613929"
FT   MUTAGEN         351
FT                   /note="Y->F: No effect on interaction with CSK."
FT                   /evidence="ECO:0000269|PubMed:10801129"
FT   MUTAGEN         381
FT                   /note="Y->F: No effect on interaction with CSK."
FT                   /evidence="ECO:0000269|PubMed:10801129"
FT   MUTAGEN         409
FT                   /note="Y->F: No effect on interaction with CSK."
FT                   /evidence="ECO:0000269|PubMed:10801129"
FT   TURN            299..301
FT                   /evidence="ECO:0007829|PDB:2RSY"
FT   HELIX           307..312
FT                   /evidence="ECO:0007829|PDB:2RSY"
SQ   SEQUENCE   424 AA;  45915 MW;  49ED52D44B3FB154 CRC64;
     MGPAGSALSS GQMQMQMVLW GSLAAVAMFF LITFLILLCS SCDRDKKPRQ HSGDHESLMN
     VPSDKEMFSH SATSLTTDAL ASSEQNGVLT NGDILSEDST MTCMQHYEEV QTSASDLLDS
     QDSTGKAKCH QSRELPRIPP ENAVDAMLTA RAADGDSGPG VEGPYEVLKD SSSQENMVED
     CLYETVKEIK EVADKSQGGK SKSTSALKEL QGAHAEGKAD FAEYASVDRN KKCRHSTNAE
     SILGTSSDLD EETPPPVPVK LLDENANLPE KGEHGAEEQA PEAPSGHSKR FSSLSYKSRE
     EDPTLTEEEI SAMYSSVNKP GQSAHKPGPE STCQCPQGPP QRSSSSCNDL YATVKDFEKT
     PNSISMLPPA RRPGEEPEPD YEAIQTLNRE DDKVPLGTNG HLVPKENDYE SIGDLQQGRD
     VTRL
//
